Results from use of Cantargia’s antibodies against IL1RAP published in scientific journal Blood

An article by Cantargia AB’s (“Cantargia”) founder and Board member Dr Thoas Fioretos and founder Dr Marcus Järås has been published in the respected scientific journal Blood . In the article, Cantargia’s antibodies are utilized in the treatment of chronic myeloid leukemia (CML) in preclinical models.

The article describes studies in preclinical models of chronic myeloid leukemia. The results show a positive effect in these disease models from the use of antibodies against IL1RAP. In particular, a clear treatment effect was evident in “PDX” models, where tumour cells derived directly from patients are treated. The researchers show that CAN04 hones in on the cancer cells and kills them by attracting cells from the immune system. In the article they also show that the interleukin-1 system plays a role in the growth of leukemia stem cells and that CAN04 can curb the growth of these by blocking signals from IL1. The results provide important information that can be of importance also for other forms of cancer. Blood is a leading scientific journal published by the American Society of Hematology (ASH).

“We are very pleased that a leading international journal like Blood has chosen to publish data from studies with Cantargia’s antibodies” , Göran Forsberg, CEO of Cantargia, says.

The article is available at www.bloodjournal.org.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60
E-mail: goran.forsberg@cantargia.com
Certified Adviser: Sedermera Fondkommission

This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 13 September 2016, at 4 pm.

About Us

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and arrest the inflammation of the tumour. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor associated protein “IL1RAP”, in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The company has selected a product candidate, CAN04, for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer. Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.

Subscribe

Documents & Links